Efficacy and tolerability of once-daily grepafloxacin compared with clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis

Clinical Drug Investigation

Volumn 17, Issue 1, 1999, Pages 21-31

  DeAbate, C Andrew ^a,f   Myers, Douglas ^b   Henry, Dan ^c   Upchurch, John ^d   Lecara, Grace ^e   Giguere, Gregory ^e   Collins, Jeffrey J ^e  

^a Woodmere Medical Center   (United States)

^b PrimeCare   (United States)

^c Foothill Family Clinic   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Medical Research Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; GREPAFLOXACIN;

ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; UNITED STATES;

EID: 0032944556     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917010-00003     Document Type: Article

References (23)

1. Enright PL, Kronmal RA, Higgins MW, et al. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 1994; 106: 827-34
2. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
3. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465-74
4. Kayser FH. Changes in the spectrum of organisms causing respiratory tract infections: a review. Postgrad Med J 1992; 68 Suppl 3: S17-23
5. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations - a meta-analysis. JAMA 1995; 273: 957-60
6. Thornsberry C. Emerging resistance in clinically important gram-positive cocci. West J Med 1996; 164: 28-32
7. Campbell G, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998; 26: 1188-95
8. Venkatsen P, Innes J. Antibiotic resistance in common acute respiratory pathogens. Thorax 1995; 50: 481-3
9. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997; 29: 249-57
10. Doern GV, Brueggemann A, Holley Jr HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-13
11. Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997; 41: 292-7
12. Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 2884-6
13. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99: 3S-7S
14. Imada T, Miyazaki S, Nishida M, et al. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother 1992; 36: 573-9
15. Marco F, Jones RN, Hoban DJ, et al. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J Antimicrob Chemother 1994; 33: 647-54
16. Cook PJ, Andrews JM, Wise R, et al. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995; 35: 317-26
17. Efthymiopoulos C, Bramer SL, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet 1997; 33 Suppl. 1: 1-8
18. Peters D, Clissold S. Clarithromycin: a review of its antimicrobial activity. Pharmacokinet Prop Ther Potential 1992; 44: 117-64
19. NCCLS. Performance Standards for Antimicrobial Disk Susceptibility Tests. 6th ed. Approved Standard M2-A6 (ISBN 1-56238-308-6). National Committee for Clinical Laboratory Standards; Wayne, PA: 1997
20. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 4th ed. Approved Standard M7-A4 (ISBN 1-56238-309-4). National Committee for Clinical Laboratory Standards; Wayne, PA: 1997
21. Langan CE, Cranfield R, Breisch S, et al. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 Suppl. A: 63-72
22. Chodosh S, Lakshminarayan S, Swarz H, et al. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998; 42: 114-20
23. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agent Dis 1994; 3: 266-73